<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …”

Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group.... by Elie Mulhem (22537863)

“…Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group. …”

Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group.... by Elie Mulhem (22537863)

“…Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group. …”

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Linear regressions of consumer stable carbon and nitrogen isotope values and collection date. by Nathan D. McTigue (10706460)

Subjects:

Association between the sum of health behaviors and decrease in physical health from before to during the pandemic. Results are from linear model analysis adjusted for age, gender and additional covariates.... by Elie Mulhem (22537863)

“…Results are from linear model analysis adjusted for age, gender and additional covariates. …”

Linear regressions of pPOM and sPOM stable carbon and nitrogen isotope values versus collection date. by Nathan D. McTigue (10706460)

Subjects:

Estimated mean values for light interception. by Torsten Schober (20485754)

Subjects:

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Results from linear regression analysis for δ¹³C or δ¹⁵N and collection date. by Nathan D. McTigue (10706460)

Subjects:

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: